NCT03971513

Brief Summary

The primary purpose of TAPAS study is to demonstrate the superiority of analgesic effect of trans abdominal plane block (TAP block) performed at the beginning of stoma reversal, compared to standard of care. The hypothesize is that a TAP block performed at the beginning of surgery of stoma reversal would improve patient's satisfaction (evaluated by Quo-r40 questionnaire), would reduce the incidence of post operative pain, time spent in recovery room, and reduce hospitalisation time

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
149

participants targeted

Target at P50-P75 for not_applicable surgery

Timeline
Completed

Started Jun 2019

Longer than P75 for not_applicable surgery

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 20, 2019

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 3, 2019

Completed
14 days until next milestone

Study Start

First participant enrolled

June 17, 2019

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 17, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 17, 2023

Completed
Last Updated

April 18, 2023

Status Verified

April 1, 2023

Enrollment Period

3.8 years

First QC Date

May 20, 2019

Last Update Submit

April 17, 2023

Conditions

Keywords

Prospective randomized pilot studyTrans abdominal plane blockQuo R 40 scorePost operative pain

Outcome Measures

Primary Outcomes (1)

  • Quo 40 score

    Once the patient is transferred in post operative surgical service, assessment of the primary outcome will be done by the physician in charge of the patient. Quo 40 score is a postoperative recovery score above 200 points validated by Myles et al in 2001.

    Day 1 (

Secondary Outcomes (5)

  • NRS (Numeric rating scale)

    Day 1 : At the entrance of recovery room

  • NRS (Numeric rating scale)

    Day 1

  • NRS (Numeric rating scale)

    Day 2

  • Quo 40 score

    Day 15

  • Time spent in recovery room

    At the output of recovery room ie until 6 hours after intervention

Study Arms (2)

usual practice

NO INTERVENTION

Control group (usual practice): patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen, nefopam and morphine. if necessary. Antimicrobial prophylaxis is performed according to recommendations

TAP block

EXPERIMENTAL

In addition of usual practice, patients receiving a TAP block at the beginning of the surgery

Procedure: Trans abdominal plane

Interventions

Trans abdominal plane block is performed with ultra sound guidance. 1. \- The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen). 2. \- When the needle is visualised in the plan separating the muscle internal oblicum and transversal of the abdomen, 20 ml of ropivacaïne 5mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised.

TAP block

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \> 18 years old
  • Patients operated of a scheduled stoma reversal surgery
  • Patients having given consent in the mannen described in Article L1122-1-1 of the Public Health Code
  • Patients affiliated with asocial security regimen or beneficiary of such a regimen

You may not qualify if:

  • Renal insufficiency (ie glomerular filtration output \< 35 ml/min)
  • Patients with chronic inflammatory bowel disease
  • Body mass index \> 35 kg/m2
  • Chronic pain with opiates
  • Patients with cognitive troubles
  • Coagulation disorders (platelets count \< 80G/L, PT\< 50%, V factor \< 50%)
  • Pregnancy
  • Breastfeeding
  • Local anesthesics (amide class) allergy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CHU

Clermont-Ferrand, France

Location

CHU Rennes

Rennes, 35033, France

Location

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Marie Vignaud

    CHU Clermont-Ferrand.fr

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Model description: Randomization in 2 groups * Control group (usual practice): patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen, nefopam and morphine if necessary Antimicrobial prophylaxis is performed according to recommendations. * Experimental group: patients receiving a general anaesthesia with propofol, sufentanyl and cisatracurium for the induction, and sevoflurane, sufentanyl and cisatracurium for the maintenance. Patients receiving a multimodal intravenous analgesia, with acetaminophen, ketoprophen, nefopan and morphine if necessary Antimicrobial prophylaxis is performed according to recommendations. In this group, a trans abdominal plane block, using 20 ml of ropivacaine 5 mg/ml is performed at the beginning of surgery, using ultrasound guidance.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 20, 2019

First Posted

June 3, 2019

Study Start

June 17, 2019

Primary Completion

April 17, 2023

Study Completion

April 17, 2023

Last Updated

April 18, 2023

Record last verified: 2023-04

Locations